Table 1 Demographics and clinical characteristics of the study eyes
Characteristics | no ME recurrence group (n = 21) | ME recurrence group (n = 22) | p-value |
|---|---|---|---|
Mean age (year) | 60.29 ± 14.26 | 64.00 ± 9.08 | 0.318* |
Male /Female (no.) | 8/13 | 7/15 | 0.667† |
Right eye/Left eye (no.) | 9/12 | 9/13 | 0.897† |
Occlusion site, no. (%) | 0.650† | ||
Major BRVO | 10 (47.6%) | 12 (54.5%) | |
Macular BRVO | 11 (52.4%) | 10 (45.5%) | |
Presence of macular hemorrhage, no. (%) | 14 (66.7%) | 16 (72.7%) | 0.665† |
Mean logMAR BCVA at first visit | 0.54 ± 0.45 | 0.61 ± 0.37 | 0.371* |
Mean logMAR BCVA at 6 months | 0.17 ± 0.21 | 0.33 ± 0.31 | 0.037* |
Mean CMT before treatment | 494.43 ± 164.62 um | 550.82 ± 161.31 um | 0.170* |
Mean CMT at ME resolution | 201.38 ± 32.17 um | 194.05 ± 38.04 um | 0.502* |
Mean time to ME resolution, months | 2.87 ± 2.16 | 2.30 ± 1.63 | 0.313* |
Mean number of intravitreal injections | 2.05 ± 1.12 | 2.86 ± 1.32 | 0.028* |
Mean follow-up period, months (range) | 8.38 ± 3.14 (6–15) | 11.09 ± 4.82 (6–21) | 0.036* |